Is the business good?
How good a business is OGN?
Organon & Co. keeps 3.4% of every revenue dollar as profit after everything, against 18% for the median Drug Manufacturers - General name.
3.4%
Net margin · Drug Manufacturers - General median 18% · 12 months to Q2 2026
- Cash conversion
- 2.71×
Cash conversion · 0.94× a year ago · every dollar of reported profit arrived as cash, and more
- Share count, year on year
- +4.0%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 5.8%
R&D as % of revenue
Details›
- Gross margin12 months to Q2 2026
- 53%
- Net margin12 months to Q2 2026
- 3.4%
- Free cash flow margin
- 9.3%
- R&D as % of revenue
- 5.8%
- Revenue, trailing twelve months
- $6.13B
- Free cash flow, trailing twelve months
- $567M
- Net income, trailing twelve months
- $209M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - General
Ranks #16 of 16 by Smart Score